The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma

BACKGROUND: We investigated the treatment outcomes and hepatic reserve of transarterial chemoembolization (TACE)-refractory patients with recurrent advanced hepatocellular carcinoma (HCC) treated with TACE plus sorafenib. METHODS: Forty-one patients with intermediate-stage HCC defined as being TACE...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Asian Pac J Cancer Prev
Autors principals: Kaibori, Masaki, Matsushima, Hideyuki, Ishizaki, Morihiko, Kosaka, Hisashi, Matsui, Kosuke, Kariya, Shuji, Yoshii, Kengo, Sekimoto, Mitsugu
Format: Artigo
Idioma:Inglês
Publicat: West Asia Organization for Cancer Prevention 2021
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8325117/
https://ncbi.nlm.nih.gov/pubmed/33906315
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.31557/APJCP.2021.22.4.1217
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars